alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 788 studies published 2014 (page 6 of 32) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA psychiatry 2014-07-01

Alterations in the hippocampus were evident across psychotic disorders. 2 key findings →

Design: case-control study Participants: 219 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Microvascular network alterations in the retina of patients with Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-01-15

Patients with AD have altered microvascular network in the retina (narrower retinal venules and a sparser and more tortuous retinal vessels) compared with matched nondemented controls. 3 key findings →

Design: case-control study Participants: 136 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Comorbidity of dementia: a cross-sectional study of primary care older patients

✓ Peer-reviewed alzhub usefulness score 62 out of 100. BMC psychiatry 2014-03-20

The analysis of the comorbidities associated with an index disease (e.g., dementia) must not be exclusively based on prevalence rates, but rather on methodologies that allow the discovery of non-random associations between diseases. 4 key findings →

Design: cross-sectional Participants: 72,815 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The Journal of pharmacology and experimental therapeutics 2014-10-15

Methylthioninium (MT) is a tau aggregation inhibitor with therapeutic potential in Alzheimer's disease (AD). 1 key finding →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source

Deep learning based imaging data completion for improved brain disease diagnosis

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention 2014-01-01

Combining multi-modality brain data for disease diagnosis commonly leads to improved performance. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Elevated serum pesticide levels and risk for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. JAMA neurology 2014-03-01

Levels of DDE were 3.8-fold higher in the serum of those with AD (mean [SEM], 2.64 [0.35] ng/mg cholesterol) when compared with control participants (mean [SEM], 0.69 [0.1] ng/mg cholesterol; P Conclusions and relevance Elevated serum DDE levels are associated with an increased risk for AD and carriers of an APOE4 ε4 allele may be more susceptible to the effects of DDE. 2 key findings →

Design: case-control study Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Clinical trials (London, England) 2014-06-05

The Systolic Blood Pressure Intervention Trial will provide important information on the risks and benefits of intensive blood pressure treatment targets in a diverse sample of high-risk participants, including those with prior cardiovascular disease, chronic kidney disease, and those aged ≥75 years. 4 key findings →

Participants: 9,361 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. JAMA neurology 2014-12-01

Patients with moderate to severe AD presented with higher mean (SD) orexin levels compared with controls (154.36 [28.16] vs 131.03 [26.55]; P Conclusions and relevance Our results demonstrate that, in AD, increased cerebrospinal fluid orexin levels are related to a parallel sleep deterioration, which appears to be associated with cognitive decline. 2 key findings →

Design: case-control study Participants: 48 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Because of the aging population and a rise in the number of stroke survivors, the prevalence of post-stroke cognitive impairment (PSCI) is increasing. 4 key findings →

Design: cohort study Participants: 280 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014-08-15

Delirium is a profound neuropsychiatric disturbance precipitated by acute illness. 4 key findings →

Design: longitudinal study Participants: 465 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Movement disorders : official journal of the Movement Disorder Society 2014-11-07

Cognitive impairment is one of the earliest, most common, and most disabling non-motor symptoms in Parkinson's disease (PD). 4 key findings →

Design: cohort study Participants: 360 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of the American Medical Directors Association 2014-12-15

This study indicates no benefits for memantine in the long-term treatment and prophylaxis of clinically significant neuropsychiatric symptoms. 5 key findings →

Participants: 199 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Science translational medicine 2014-03-01

Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD) begins many years before the appearance of cognitive symptoms. 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Physical activity attenuates age-related biomarker alterations in preclinical AD

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2014-10-08

In a middle-aged, at-risk cohort, a physically active lifestyle is associated with an attenuation of the deleterious influence of age on key biomarkers of AD pathophysiology. 3 key findings →

Design: cross-sectional Participants: 186 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

2014 Alzheimer's disease facts and figures

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-03-01

This report discusses the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. 2 key findings →

Participants: 200,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed